Miriam Freimer — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications2liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Zilucoplan®This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.	Myasthénie	Phase 3	À vérifier	United States	À vérifier
Zilucoplan®This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.	Myasthénie	Phase 3	À vérifier	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Zilucoplan®	Myasthénie	Phase 3	NCT07215949	Zilucoplan for Severe gMG Exacerbations	RECRUITING

Publications

2

Molécule	Indication / population	Titre	Journal	Date
Zilucoplan®		Zilucoplan-Associated Morpheaform Skin Changes and Methotrexate and UVA1 Phototherapy.	JAMA dermatology
Zilucoplan®		Fibrosing Skin Disorder Associated With Zilucoplan.	JAMA dermatology